title: DRAR-CPI: a server for identifying drug repositioning potential and adverse drug reactions via the chemical-protein interactome.
abstract: Identifying new indications for existing drugs (drug repositioning) is an efficient way of maximizing their potential. Adverse drug reaction (ADR) is one of the leading causes of death among hospitalized patients. As both new indications and ADRs are caused by unexpected chemical-protein interactions on off-targets, it is reasonable to predict these interactions by mining the chemical-protein interactome (CPI). Making such predictions has recently been facilitated by a web server named DRAR-CPI. This server has a representative collection of drug molecules and targetable human proteins built up from our work in drug repositioning and ADR. When a user submits a molecule, the server will give the positive or negative association scores between the user's molecule and our library drugs based on their interaction profiles towards the targets. Users can thus predict the indications or ADRs of their molecule based on the association scores towards our library drugs. We have matched our predictions of drug-drug associations with those predicted via gene-expression profiles, achieving a matching rate as high as 74%. We have also successfully predicted the connections between anti-psychotics and anti-infectives, indicating the underlying relevance of anti-psychotics in the potential treatment of infections, vice versa. This server is freely available at http://cpi.bio-x.cn/drar/.
authors.affiliation: Bio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders (Ministry of Education), Shanghai Jiao Tong University, Shanghai, China.
authors.forename: Heng
authors.initials: H
authors.lastname: Luo
authors.forename: Jian
authors.initials: J
authors.lastname: Chen
authors.forename: Leming
authors.initials: L
authors.lastname: Shi
authors.forename: Mike
authors.initials: M
authors.lastname: Mikailov
authors.forename: Huang
authors.initials: H
authors.lastname: Zhu
authors.forename: Kejian
authors.initials: K
authors.lastname: Wang
authors.forename: Lin
authors.initials: L
authors.lastname: He
authors.forename: Lun
authors.initials: L
authors.lastname: Yang
mesh_terms: D000890:Anti-Infective Agents / Q000009:adverse effects / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use; D058492:Drug Repositioning; D064420:Drug-Related Side Effects and Adverse Reactions / Q000517:prevention & control*; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use; D020407:Internet; D008024:Ligands; D004364:Pharmaceutical Preparations / Q000737:chemistry; D011506:Proteins / Q000737:chemistry; D000077154:Rosiglitazone; D012984:Software; D045162:Thiazolidinediones / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D000890:Anti-Infective Agents; D014150:Antipsychotic Agents; D007004:Hypoglycemic Agents; D008024:Ligands; D004364:Pharmaceutical Preparations; D011506:Proteins; D045162:Thiazolidinediones; D000077154:Rosiglitazone